[1]
L. Pradelli and P. Ascierto, “[Reply to Letter to the Editor in reference to " Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]”, FE, vol. 18, no. 1, Sep. 2017.